# A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer

> **NCT02341404** · PHASE2 · COMPLETED · sponsor: **Lidds AB** · enrollment: 23 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 2-hydroxyflutamide (2-HOF)

## Key facts

- **NCT ID:** NCT02341404
- **Lead sponsor:** Lidds AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02341404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02341404, "A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02341404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*